6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Interferon‐β regulates the production of IL‐10 by toll‐like receptor‐activated microglia

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pattern recognition receptors, such as toll‐like receptors (TLRs), perceive tissue alterations and initiate local innate immune responses. Microglia, the resident macrophages of the brain, encode TLRs which primary role is to protect the tissue integrity. However, deregulated activation of TLRs in microglia may lead to chronic neurodegeneration. This double role of microglial responses is often reported in immune‐driven neurologic diseases, as in multiple sclerosis (MS). Consequently, strategies to manipulate microglia inflammatory responses may help to ameliorate disease progression. In this context, the anti‐inflammatory cytokine interleukin (IL)‐10 appears as an attractive target. In this study, we investigated how activation of microglia by TLRs with distinct roles in MS impacts on IL‐10 production. We found that activation of TLR2, TLR4, and TLR9 induced the production of IL‐10 to a greater extent than activation of TLR3. This was surprising as both TLR3 and IL‐10 play protective roles in animal models of MS. Interestingly, combination of TLR3 triggering with the other TLRs, enhanced IL‐10 through the modulation of its transcription, via interferon (IFN)‐β, but independently of IL‐27. Thus, in addition to the modulation of inflammatory responses of the periphery described for the axis TLR3/IFN‐β, we now report a direct modulation of microglial responses. We further show that the presence of IFN‐γ in the microenvironment abrogated the modulation of IL‐10 by TLR3, whereas that of IL‐17 had no effect. Considering the therapeutic application of IFN‐β in MS, our study bears important implications for the understanding of the cytokine network regulating microglia responses in this setting.

          Main Points

          • TLR triggering impacts IL‐10 production by microglia.

          • IL‐10 production by microglial cells is transcriptionally enhanced by IFN‐β.

          • Cytokine micro‐environment impacts IL‐10 production by microglial cells, with IFN‐? hampering its production.

          Related collections

          Most cited references57

          • Record: found
          • Abstract: found
          • Article: not found

          Il10 deficiency rebalances innate immunity to mitigate Alzheimer-like pathology.

          The impact of inflammation suppressor pathways on Alzheimer's disease (AD) evolution remains poorly understood. Human genetic evidence suggests involvement of the cardinal anti-inflammatory cytokine, interleukin-10 (IL10). We crossed the APP/PS1 mouse model of cerebral amyloidosis with a mouse deficient in Il10 (APP/PS1(+)Il10(-/-)). Quantitative in silico 3D modeling revealed activated Aβ phagocytic microglia in APP/PS1(+)Il10(-/-) mice that restricted cerebral amyloidosis. Genome-wide RNA sequencing of APP/PS1(+)Il10(-/-) brains showed selective modulation of innate immune genes that drive neuroinflammation. Il10 deficiency preserved synaptic integrity and mitigated cognitive disturbance in APP/PS1 mice. In vitro knockdown of microglial Il10-Stat3 signaling endorsed Aβ phagocytosis, while exogenous IL-10 had the converse effect. Il10 deficiency also partially overcame inhibition of microglial Aβ uptake by human Apolipoprotein E. Finally, the IL-10 signaling pathway was abnormally elevated in AD patient brains. Our results suggest that "rebalancing" innate immunity by blocking the IL-10 anti-inflammatory response may be therapeutically relevant for AD.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            T(H)1 cells control themselves by producing interleukin-10.

            Inflammatory T helper 1 (T(H)1)-cell responses successfully eradicate pathogens, but often also cause immunopathology. To minimize this deleterious side-effect the anti-inflammatory cytokine interleukin-10 (IL-10) is produced. Although IL-10 was originally isolated from T(H)2 cells it is now known to be produced by many cell types. Here, we discuss the recent evidence that shows that T(H)1 cells are the main source of IL-10 that controls the immune response against Leishmania major and Toxoplasma gondii infection.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              IL-10 alters immunoproteostasis in APP mice, increasing plaque burden and worsening cognitive behavior.

              Anti-inflammatory strategies are proposed to have beneficial effects in Alzheimer's disease. To explore how anti-inflammatory cytokine signaling affects Aβ pathology, we investigated the effects of adeno-associated virus (AAV2/1)-mediated expression of Interleukin (IL)-10 in the brains of APP transgenic mouse models. IL-10 expression resulted in increased Aβ accumulation and impaired memory in APP mice. A focused transcriptome analysis revealed changes consistent with enhanced IL-10 signaling and increased ApoE expression in IL-10-expressing APP mice. ApoE protein was selectively increased in the plaque-associated insoluble cellular fraction, likely because of direct interaction with aggregated Aβ in the IL-10-expressing APP mice. Ex vivo studies also show that IL-10 and ApoE can individually impair glial Aβ phagocytosis. Our observations that IL-10 has an unexpected negative effect on Aβ proteostasis and cognition in APP mouse models demonstrate the complex interplay between innate immunity and proteostasis in neurodegenerative diseases, an interaction we call immunoproteostasis.
                Bookmark

                Author and article information

                Contributors
                margarida.saraiva@ibmc.up.pt
                Journal
                Glia
                Glia
                10.1002/(ISSN)1098-1136
                GLIA
                Glia
                John Wiley and Sons Inc. (Hoboken )
                0894-1491
                1098-1136
                15 June 2017
                September 2017
                : 65
                : 9 ( doiID: 10.1002/glia.v65.9 )
                : 1439-1451
                Affiliations
                [ 1 ] Life and Health Sciences Research Institute (ICVS), School of Medicine University of Minho Braga Portugal
                [ 2 ] ICVS/3B's PT Government Associate Laboratory Braga/Guimarães Portugal
                [ 3 ] i3S ‐ Instituto de Investigação e Inovação em Saúde, Universidade do Porto Porto Portugal
                [ 4 ] IBMC – Instituto de Biologia Molecular e Celular, Universidade do Porto Porto Portugal
                Author notes
                [*] [* ] Correspondence Margarida Saraiva, i3S ‐ Instituto de Investigação e Inovação em Saúde, Rua Alfredo Allen, 208, 4200‐135 Porto, Portugal. Email: margarida.saraiva@ 123456ibmc.up.pt
                Author information
                http://orcid.org/0000-0002-9580-6618
                http://orcid.org/0000-0002-8180-1293
                Article
                GLIA23172
                10.1002/glia.23172
                7165667
                28617991
                8ce30ffa-f7dd-443d-91d9-5d4ebc342f3a
                © 2017 Wiley Periodicals, Inc.

                This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

                History
                : 30 December 2016
                : 09 May 2017
                : 10 May 2017
                Page count
                Figures: 5, Tables: 0, Pages: 13, Words: 8998
                Funding
                Funded by: Portuguese Foundation for Science and Technology (FCT)
                Award ID: SFRH/BD/88081/2012
                Award ID: SFRH/BPD/72710/2010
                Funded by: FEDER ‐ Competitiveness Factors Operational Programme (COMPETE) , open-funder-registry 10.13039/501100002924;
                Award ID: POCI‐01‐0145‐FEDER‐007038
                Award ID: NORTE‐01‐0145‐FEDER‐000013
                Funded by: Norte Portugal Regional Operational Programme, PORTUGAL 2020, European Regional Development Fund (ERDF)
                Award ID: NORTE 2020
                Funded by: FCT‐ANR
                Award ID: FCT‐ANR/BIM‐MEC/0007/2013
                Funded by: FEDER ‐ Fundo Europeu de Desenvolvimento Regional , open-funder-registry 10.13039/501100002924;
                Funded by: COMPETE 2020 ‐ Operacional Programme for Competitiveness and Internationalisation (POCI), Portugal 2020
                Funded by: Institute for Research and Innovation in Health Sciences
                Award ID: POCI‐01‐0145‐FEDER‐007274
                Categories
                Research Article
                Research Articles
                Custom metadata
                2.0
                September 2017
                Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.0 mode:remove_FC converted:15.04.2020

                Neurosciences
                anti‐inflammation,cytokines,innate immunity,multiple sclerosis,neurodegeneration
                Neurosciences
                anti‐inflammation, cytokines, innate immunity, multiple sclerosis, neurodegeneration

                Comments

                Comment on this article